1. Pre-hospital antiplatelet medication use on COVID-19 disease severity
- Author
-
Darren Pan, Jeong Yun Yang, Alexandra Z. Agathis, Madhu Mazumdar, Isaac Wasserman, Hooman D. Poor, Akila Pai, Serena Zhan, Daniel J. Snyder, Nikhil Shamapant, and Ada Ip
- Subjects
Adult ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,Critical Care and Intensive Care Medicine ,medicine.disease_cause ,Severity of Illness Index ,Article ,03 medical and health sciences ,0302 clinical medicine ,Severity of illness ,Acute lung injury ,medicine ,Extracorporeal membrane oxygenation ,Clinical endpoint ,Humans ,Antiplatelet ,Intubation ,Retrospective Studies ,Aspirin ,SARS-CoV-2 ,business.industry ,COVID-19 ,Thrombosis ,Retrospective cohort study ,medicine.disease ,Hospitals ,Hospitalization ,030228 respiratory system ,Emergency medicine ,Cardiology and Cardiovascular Medicine ,business ,Nasal cannula ,Platelet Aggregation Inhibitors ,medicine.drug - Abstract
Objective To evaluate the association between pre-hospitalization antiplatelet medication use and COVID-19 disease severity. Design Retrospective cohort study. Setting Inpatient units at The Mount Sinai Hospital. Patients Adults age ≥18 admitted between March 1, 2020 and April 9, 2020 with confirmed COVID-19 infection with at least 28 days follow-up. Measurements We captured baseline demographic, pre-hospitalization antiplatelet medication use, and clinical encounter data for all patients who met inclusion criteria. The primary endpoint was peak score on a 6-point modified ordinal scale (MOS), which is based on World Health Organization blueprint R&S groups, used to grade severity of illness through clinical outcomes of interest. Scores indicate the following: 1 – COVID-19 infection not requiring hospitalization, 2 – requiring hospitalization but not supplemental oxygen, 3 – hospitalization requiring supplemental oxygen, 4 – hospitalization requiring high-flow nasal cannula (HFNC) or non-invasive positive pressure ventilation (NIPPV), 5 – hospitalization requiring intubation or extracorporeal membrane oxygenation (ECMO), 6 – death. Multivariable adjusted partial proportional odds model (PPOM) was performed to examine the association between pre-hospitalization antiplatelet medication use and likelihood of each MOS score. Main Results Of 762 people admitted with COVID-19, 239 (31.4%) used antiplatelet medications pre-hospitalization while 523 (68.6%) did not. Antiplatelet users were older and had more co-morbidities at baseline. Before adjusting for covariates, patients who used antiplatelet medications pre-hospitalization were more likely than non-users to have peak MOS score 6 (death, OR 1.75, 95% CI 1.21–2.52), peak MOS score ≥5 (intubation/ECMO or death, OR 1.4, 95% CI 1.00–1.98) and peak MOS score ≥4 (HFNC, NIPPV, intubation/ECMO or death, OR 1.40, 95% CI 1.01–1.94). On multivariable adjusted PPOM analysis controlling for 13 covariates, there were no longer any significant differences in peak MOS scores between users and non-users. Conclusions After adjusting for covariates, pre-hospital antiplatelet use was not associated with COVID-19 severity in hospitalized patients.
- Published
- 2021
- Full Text
- View/download PDF